Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PNC044
MIFTS: 61

Pancreatitis

Categories: Bone diseases, Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pancreatitis

About this section

MalaCards integrated aliases for Pancreatitis:

Name: Pancreatitis 12 25 29 54 6 42 15 39 17 71

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Endocrine diseases Gastrointestinal diseases Bone diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:4989
MeSH 44 D010195
NCIt 50 C3306
SNOMED-CT 67 393591004
ICD10 32 K85.9
UMLS 71 C0030305
Sources

Summaries for Pancreatitis

About this section
MedlinePlus : 42 The pancreas is a large gland behind the stomach and close to the first part of the small intestine. It secretes digestive juices into the small intestine through a tube called the pancreatic duct. The pancreas also releases the hormones insulin and glucagon into the bloodstream. Pancreatitis is inflammation of the pancreas. It happens when digestive enzymes start digesting the pancreas itself. Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. Acute pancreatitis occurs suddenly and usually goes away in a few days with treatment. It is often caused by gallstones. Common symptoms are severe pain in the upper abdomen, nausea, and vomiting. Treatment is usually a few days in the hospital for intravenous (IV) fluids, antibiotics, and medicines to relieve pain. Chronic pancreatitis does not heal or improve. It gets worse over time and leads to permanent damage. The most common cause is heavy alcohol use. Other causes include cystic fibrosis and other inherited disorders, high levels of calcium or fats in the blood, some medicines, and autoimmune conditions. Symptoms include nausea, vomiting, weight loss, and oily stools. Treatment may also be a few days in the hospital for intravenous (IV) fluids, medicines to relieve pain, and nutritional support. After that, you may need to start taking enzymes and eat a special diet. It is also important to not smoke or drink alcohol. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Pancreatitis is related to pancreatitis, hereditary and tropical calcific pancreatitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Pancreatitis is SPINK1 (Serine Peptidase Inhibitor Kazal Type 1), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Salivary secretion. The drugs Cefoperazone and Iron have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and pancreatic islet, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Pancreatitis is a condition characterized by inflammation of the pancreas. The pancreas is a large organ... more...

GeneReviews: NBK190101
Sources

Related Diseases for Pancreatitis

About this section

Diseases in the Pancreatitis family:

Pancreatitis, Hereditary Autoimmune Pancreatitis
Acute Pancreatitis Prss1-Related Hereditary Pancreatitis
Autoimmune Pancreatitis Type 2 Autoimmune Pancreatitis Type 1

Diseases related to Pancreatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1448)
# Related Disease Score Top Affiliating Genes
1 pancreatitis, hereditary 33.2 SPINK1 SCT REG1A PRSS2 PRSS1 CTRC
2 tropical calcific pancreatitis 33.1 SPINK1 REG1A PRSS2 PRSS1 CTRC
3 acute pancreatitis 32.7 VMP1 SST SPINK1 SCT REG3A PRSS1
4 alcoholic pancreatitis 32.6 SPINK1 SCT REG3A PRSS1 LPL CPB1
5 prss1-related hereditary pancreatitis 32.4 SPINK1 PRSS2 PRSS1 CTRC CFTR
6 familial lipoprotein lipase deficiency 32.3 PNLIP LPL APOC2
7 pancreatic cancer 32.1 SST SPINK1 SCT REG3A REG1A PRSS1
8 hyperlipoproteinemia, type i 32.1 PNLIP LPL APOC2
9 cholangitis 32.0 SST CRP CFTR
10 mikulicz disease 32.0 SPINK1 CRP
11 glucagonoma 32.0 SST SCT
12 lipase deficiency, combined 31.9 PNLIP LPL
13 cholelithiasis 31.7 SST CRP CCK
14 pancreatic agenesis 1 31.6 SPINK1 SCT PNLIP CFTR
15 ileus 31.5 SST CRP CFTR CCK
16 cystic fibrosis 31.5 SPINK1 REG3A PRSS1 LPL CRP CFTR
17 bile duct cysts 31.4 SPINK1 PRSS1
18 duodenal obstruction 31.4 SPINK1 SCT PRSS1 CRP
19 exocrine pancreatic insufficiency 31.4 SPINK1 SCT PNLIP CFTR CCK
20 cholangitis, primary sclerosing 31.4 SCT CRP CFTR
21 biliary dyskinesia 31.4 SST SPINK1 SCT REG3A PRSS1 CFTR
22 duodenal ulcer 31.3 SST SCT CCK
23 pancreas, annular 31.1 SPINK1 PRSS1
24 bile reflux 31.0 SCT CCK
25 gallbladder disease 31.0 SST CRP CFTR CCK
26 diarrhea 31.0 SST SCT CFTR CCK
27 acalculous cholecystitis 30.9 CRP CCK
28 parotitis 30.9 SPINK1 CRP
29 gastroparesis 30.9 SST SCT CCK
30 duodenitis 30.8 CRP CCK
31 glucose intolerance 30.8 SST LPL CRP
32 neuroendocrine tumor 30.8 SST SCT CCK
33 uremia 30.8 LPL CRP CASR
34 cholecystolithiasis 30.8 SST CRP CCK
35 diabetes mellitus 30.7 SST SPINK1 SCT REG1A PNLIP LPL
36 irritable bowel syndrome 30.7 SST CRP CCK
37 pancreatic steatorrhea 30.6 SCT PRSS1 PNLIP CCK
38 gas gangrene 30.5 PLA2G2A CRP CPB1
39 familial hyperlipidemia 30.5 PNLIP LPL CRP APOC2
40 type 2 diabetes mellitus 30.5 SST SPINK1 SCT PNLIP PLA2G2A LPL
41 gastrinoma 30.5 SST SCT CASR
42 pancreatic acinar cell adenocarcinoma 30.3 REG1A CPA1
43 mesenteric lymphadenitis 30.2 REG3A CRP
44 intestinal pseudo-obstruction 30.2 SST SPINK1 PRSS1 CFTR
45 meckel diverticulum 30.2 SST CRP
46 maturity-onset diabetes of the young 30.2 SST REG1A LPL CRP APOC2
47 multiple endocrine neoplasia, type i 30.1 SST SCT CASR
48 bile acid malabsorption, primary 30.1 SST SCT PNLIP CFTR CCK
49 linitis plastica 30.0 PRSS2 PRSS1
50 pancreatic gastrinoma 30.0 SST SCT

Graphical network of the top 20 diseases related to Pancreatitis:



Diseases related to Pancreatitis
Sources

Symptoms & Phenotypes for Pancreatitis

About this section

UMLS symptoms related to Pancreatitis:


nausea and vomiting, constipation, abdominal pain, diarrhea, dyspepsia, icterus, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Pancreatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.23 SST
2 Decreased viability GR00249-S 9.23 CPB1 PRSS1
3 Decreased viability GR00381-A-1 9.23 SCT
4 Decreased viability GR00386-A-1 9.23 CCK LPL
5 Decreased viability GR00402-S-2 9.23 CTRC SCT

MGI Mouse Phenotypes related to Pancreatitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.61 CASR CFTR CPA1 CTRC PNLIP SPINK1
2 homeostasis/metabolism MP:0005376 9.53 APOC2 CASR CCK CFTR CPA1 CPB1
Sources

Drugs & Therapeutics for Pancreatitis

About this section

Drugs for Pancreatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 738)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefoperazone Approved, Investigational Phase 4 62893-19-0 44185
2
Iron Approved Phase 4 7439-89-6 23925 29936
3
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
4
Metformin Approved Phase 4 657-24-9 14219 4091
5
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
6
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
7
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
8
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
9
Ceftazidime Approved Phase 4 72558-82-8, 78439-06-2 5481173
10
Cilastatin Approved, Investigational Phase 4 82009-34-5 5280454 6435415
11
Glimepiride Approved Phase 4 93479-97-1 3476
12
Meperidine Approved Phase 4 57-42-1 4058
13
Etomidate Approved Phase 4 33125-97-2 36339 667484
14
Simethicone Approved Phase 4 8050-81-5
15
Titanium dioxide Approved Phase 4 13463-67-7
16
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
17
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
18
Insulin glargine Approved Phase 4 160337-95-1
19
Remifentanil Approved Phase 4 132875-61-7 60815
20
Desflurane Approved Phase 4 57041-67-5 42113
21
Glycolic acid Approved, Investigational Phase 4 79-14-1 757
22
Insulin glulisine Approved Phase 4 207748-29-6
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
25
Glycerol Approved, Investigational Phase 4 56-81-5 753
26
Levodopa Approved Phase 4 59-92-7 6047
27
Thrombin Approved, Investigational Phase 4
28
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
29
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
30
Protein C Approved Phase 4
31
Methylnaltrexone Approved Phase 4 916055-93-1, 83387-25-1 6603824
32
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
33
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
34
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
35
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
36
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
37
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
38
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
39
Morphine Approved, Investigational Phase 4 57-27-2 5288826
40
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
41
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
42
Resveratrol Investigational Phase 4 501-36-0 445154
43
Nimotuzumab Investigational Phase 4 780758-10-3, 828933-61-3
44
Polygeline Experimental Phase 4 66455-30-9
45
Thymalfasin Investigational Phase 4 62304-98-7
46 Fibrin Tissue Adhesive Phase 4
47 Disinfectants Phase 4
48 Sulperazone Phase 4
49 Soybean oil, phospholipid emulsion Phase 4
50 Fat Emulsions, Intravenous Phase 4

Interventional clinical trials:

(show top 50) (show all 3188)
# Name Status NCT ID Phase Drugs
1 Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following Unknown status NCT02691598 Phase 4 Infusion
2 Escalade or Deseacalade Antibiotic Use in Severe Acute Pancreatitis Unknown status NCT01992198 Phase 4 cefoperazone + metronidazole;Somatostatin;Meropenem
3 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Unknown status NCT01642875 Phase 4
4 H.O.P.E. Healing Optimization Through Preoperative Engagement: A Prospective Single Cohort Study to Evaluate the Effect of a Prehabilitation Program on Preoperative Outcomes in Upper GI Surgical Oncology Patients Unknown status NCT03642093 Phase 4
5 Random Comparing Study on Two Different EUS-guided Pseudocyst Drainage Methods--Modified Naso-pancreatic Tube Drainage and Stents Drainage Unknown status NCT01585662 Phase 4
6 Comparative Study About the Impact of Two Oil Emulsions, One of Them Formulated With MCT, LCT, Olive Oil and Omega 3 Fatty Acids Versus Another One Formulated With MCT and LCT, Administered Intravenously on Severe Acute Pancreatitis Clinical Evolution Unknown status NCT01376817 Phase 4 Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids;Fat emulsion with MCT and LCT
7 Randomized, Controlled, Open-label Trial of Intravenous Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis. Unknown status NCT03501680 Phase 4 Insulin
8 Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal: A Prospective Study. Unknown status NCT03082469 Phase 4
9 Effect Observation Study of COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis Unknown status NCT02964403 Phase 4 Cox-2;Indomethacin
10 Comparative Evaluation of Standard Prophylaxis Versus Divided-dose NSAIDs or Hybrid NSAID and N-acetylcysteine Therapy for the Prevention of Post-ERCP Pancreatitis Unknown status NCT03708458 Phase 4 indomethacin suppository;N-acetylcysteine (NAC)
11 Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis Unknown status NCT02839356 Phase 4 epinephrine;normal saline
12 Oral Resveratrol Before ERCP Redused Overall Pancreatitis in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP): A Multi-center, Single-blinded, Randomized Controlled Trial Unknown status NCT02947932 Phase 4 Resveratrol;Indomethacin
13 Randomized, Controlled, Multicenter Studies of the Effects of Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis Unknown status NCT03342807 Phase 4 Insulin
14 Prophylactic Pancreatic Duct Stent Placement After Endoscopic Snare Papillectomy of Duodenal Major Papillary Tumors; Prospective, Randomized, Controlled Study Unknown status NCT01737463 Phase 4
15 Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET) Unknown status NCT02759718 Phase 4
16 Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
17 Prevention for Surgical Site Infection After Pancreatic Resection Unknown status NCT00661648 Phase 4
18 The Effect of Application of Fibrinogen/Thrombin-coated Collagen Patch (TachoSil®) in Pancreaticojejunostomy for Prevention of Pancreatic Fistula After Pancreatoduodenectomy Unknown status NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
19 Prospective Paired Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
20 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Unknown status NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
21 A Randomized, Controlled, Double Blind, Multicenter Study of Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Advanced or Metastatic Pancreatic Cancer After First-line Treatment Unknown status NCT02945267 Phase 4 Nimotuzumab plus S1;Placebo plus S1
22 Dual Tracer Functional Imaging of Nonfunctional Pancreatic Neuroendocrine Tumors Using 68Ga-DOTA-NOC and 18F-FDG PET/CT Unknown status NCT02621541 Phase 4
23 A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
24 Studie Naar De Effectiviteit Van Ursodeoxycholzuur Ter Preventie Van Galsteen-Gerelateerde Klachten Bij patiënten in Afwachting Van Een Cholecystectomie Completed NCT00161083 Phase 4 ursodeoxycholic acid
25 Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube Completed NCT00999232 Phase 4 Erythromycin;Placebo
26 A Prospective Study of Celiac Block Technique: One Injection or Two? Completed NCT00583479 Phase 4
27 A Multi-Center, Prospective, Randomized Study Comparing Removable, Self-Expanding Metal Stents to Plastic Stents for the Treatment of Benign Biliary Strictures Secondary to Chronic Pancreatitis Completed NCT01543256 Phase 4
28 A Multicentre, Randomised, Double-blind, Placebo-controlled, Study on the Use of Prophylactic Meropenem Therapy in Subjects With Severe Acute Necrotizing Pancreatitis Completed NCT00061438 Phase 4 meropenem
29 Enzyme Substitution in Exocrine Pancreatic Insufficiency; Self Administration Against a Fixed Dose Regimen Completed NCT01430234 Phase 4 Panzytrat 25.000 FIP-E units of Lipase
30 The Impact of Early Enteral Nutrition on the Clinical Outcomes of Severe Acute Pancreatitis Patients: A Randomized Control Trial Completed NCT00995098 Phase 4
31 Evaluation of the Digestive and Metabolic Utilisation of Dietary Protein in Patients With Chronic Pancreatitis Completed NCT00957151 Phase 4 Creon
32 Double-blind Randomized Study to Determine the Efficacy of Intramuscular Vitamin D3 Supplementation in Tropical Calcific Pancreatitis Completed NCT00956839 Phase 4 Vitamin D3 (Cholecalciferol)
33 Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP) Completed NCT02111707 Phase 4 Rectal indomethacin 100mg one time before or after ERCP
34 Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis Completed NCT00318994 Phase 4 Meropenem
35 One Week Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Center Study With Creon® 25000 Minimicrospheresâ„¢ in Subjects With Pancreatic Exocrine Insufficiency After Pancreatic Surgery, Followed by an Open-Label Long-Term Extension of 1 Year Completed NCT00535756 Phase 4 Creon;Placebo
36 Enteral Nutrition for Treatment of Acute Pancreatitis - a Prospective, Randomized Clinical Trial Completed NCT01965873 Phase 4
37 Dexmedetomidine vs Placebo in ERCP Sedation.A Randomized Pilot Study Completed NCT01070680 Phase 4 Precedex;sodium chlorid 0,9%
38 APCAP - Activated Protein C in Severe Acute Pancreatitis: A Double-blind Randomized Human Pilot Trial Completed NCT01017107 Phase 4 Activated protein C
39 DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Randomized Multi-center Study Completed NCT01744847 Phase 4
40 Diclophenac Potassium Versus Ceftazidime for Reduction of Post ERCP Pancreatitis in Average Risk Patients-double Blind, Randomised Controlled Trial Completed NCT01784445 Phase 4 Ceftazidime
41 A Double-Blind, Randomized, Placebo Controlled Intervention Study to Assess the Impact of Sitagliptin 100 mg/Day for 1 Year on Insulin Independence Following Pancreatectomy and Autoislet Transplantation Completed NCT01186562 Phase 4 Sitagliptin;Placebo
42 The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Completed NCT01507766 Phase 4 early enteral nutrition;Delayed enteral nutrition
43 Randomized Controlled Trial on Sterile Fluid Collections Management in Acute Pancreatitis Completed NCT00786929 Phase 4 Conservative treatment
44 Imipenem Prophylaxis of Infectious Complications in Patients With Acute Pancreatitis Completed NCT02897206 Phase 4 Imipenem;Placebo
45 Nutritional and Metabolic Evaluation of a Tube Feeding Immune Enhancing Diet in ICU Patients Completed NCT00560157 Phase 4
46 A Prospective Randomised Trial of 0.025 Wire Guided Cannulation Versus Current Practice 0.035 Wire Guided Cannulation Completed NCT01408264 Phase 4
47 Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
48 Prospective Study for the Effects of High Dose Pancreatic Enzyme Replacement Therapy on Body Weight, Quality of Life, and Nutritional Assessment After Pancreatoduodenectomy Completed NCT02127021 Phase 4 Norzyme® 40000 IU;Placebo
49 An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Completed NCT02823964 Phase 4 Liprotamase
50 Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D) Completed NCT02973477 Phase 4 Dapagliflozin;Glimepiride

Search NIH Clinical Center for Pancreatitis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Propantheline
Propantheline Bromide
Sources

Genetic Tests for Pancreatitis

About this section

Genetic tests related to Pancreatitis:

# Genetic test Affiliating Genes
1 Pancreatitis 29
Sources

Anatomical Context for Pancreatitis

About this section

MalaCards organs/tissues related to Pancreatitis:

40
Pancreas, Liver, Pancreatic Islet, Neutrophil, T Cells, Endothelial, Bone Marrow
Sources

Publications for Pancreatitis

About this section

Articles related to Pancreatitis:

(show top 50) (show all 30152)
# Title Authors PMID Year
1
The natural history of hereditary pancreatitis: a national series. 61 25 54
18755888 2009
2
Association between calcium sensing receptor gene polymorphisms and chronic pancreatitis in a US population: role of serine protease inhibitor Kazal 1type and alcohol. 54 61 25
18680227 2008
3
Potential role of imaging for assessing acute pancreatitis-induced acute kidney injury. 42 61
33237803 2021
4
The risk factors for acute respiratory distress syndrome in patients with severe acute pancreatitis: A retrospective analysis. 42 61
33466140 2021
5
Bibliometric analysis of acute pancreatitis in Web of Science database based on CiteSpace software. 42 61
33285696 2020
6
Variants That Affect Function of Calcium Channel TRPV6 Are Associated With Early-Onset Chronic Pancreatitis. 25 61
31930989 2020
7
Acute Pancreatitis Task Force on Quality: Development of Quality Indicators for Acute Pancreatitis Management. 25 61
31205135 2019
8
Elastase 3B mutation links to familial pancreatitis with diabetes and pancreatic adenocarcinoma. 25 61
31369399 2019
9
Genetic Risk Score in Diabetes Associated With Chronic Pancreatitis Versus Type 2 Diabetes Mellitus. 25 61
31232720 2019
10
Protease-Sensitive Pancreatic Lipase Variants Are Associated With Early Onset Chronic Pancreatitis. 25 61
30789418 2019
11
Pancreatitis: TIGAR-O Version 2 Risk/Etiology Checklist With Topic Reviews, Updates, and Use Primers. 61 25
31166201 2019
12
Chronic Pancreatitis: Pediatric and Adult Cohorts Show Similarities in Disease Progress Despite Different Risk Factors. 61 25
30897605 2019
13
Genome-wide association study identifies inversion in the CTRB1-CTRB2 locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis. 61 25
28754779 2018
14
Guidelines for the Diagnostic Cross Sectional Imaging and Severity Scoring of Chronic Pancreatitis. 25 61
30177434 2018
15
Hereditary Pancreatitis in the United States: Survival and Rates of Pancreatic Cancer. 25 61
30018304 2018
16
Recurrent Acute Pancreatitis: International State-of-the-Science Conference With Recommendations. 61 25
29894415 2018
17
Patient and Disease Characteristics Associated With the Presence of Diabetes Mellitus in Adults With Chronic Pancreatitis in the United States. 25 61
28741615 2017
18
Chronic pancreatitis. 61 25
28880010 2017
19
Guidelines for the understanding and management of pain in chronic pancreatitis. 61 25
28734722 2017
20
Validation of Demographics, Etiology, and Risk Factors for Chronic Pancreatitis in the USA: A Report of the North American Pancreas Study (NAPS) Group. 25 61
28600657 2017
21
Long-term pain relief with optimized medical treatment including antioxidants and step-up interventional therapy in patients with chronic pancreatitis. 61 25
27061119 2017
22
A recombined allele of the lipase gene CEL and its pseudogene CELP confers susceptibility to chronic pancreatitis. 25 61
25774637 2015
23
Fucosyltransferase 2 (FUT2) non-secretor status and blood group B are associated with elevated serum lipase activity in asymptomatic subjects, and an increased risk for chronic pancreatitis: a genetic association study. 25 61
25028398 2015
24
Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. 61 25
24152948 2013
25
Variants in CPA1 are strongly associated with early onset chronic pancreatitis. 25 61
23955596 2013
26
Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. 61 25
23890130 2013
27
Variation in the γ-glutamyltransferase 1 gene and risk of chronic pancreatitis. 25 61
23462328 2013
28
Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. 25 61
23100216 2013
29
Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. 61 25
23143602 2012
30
ABO blood group and chronic pancreatitis risk in the NAPS2 cohort. 61 25
21792085 2011
31
Oxidative stress in chronic pancreatitis: pathophysiological relevance and management. 25 61
21902596 2011
32
Quality of life improves for pediatric patients after total pancreatectomy and islet autotransplant for chronic pancreatitis. 25 61
21683160 2011
33
Imaging of acute pancreatitis. 25 61
21785045 2011
34
Use and perceived effectiveness of non-analgesic medical therapies for chronic pancreatitis in the United States. 61 25
21083584 2011
35
Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial. 61 25
20502447 2010
36
Therapeutic implications of oxidative stress in acute and chronic pancreatitis. 61 25
20543682 2010
37
Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. 25 61
19506173 2009
38
A randomized controlled trial of antioxidant supplementation for pain relief in patients with chronic pancreatitis. 25 61
18952082 2009
39
Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. 61 25
18184119 2008
40
Yoga: a tool for improving the quality of life in chronic pancreatitis. 61 25
17230607 2007
41
Practice guidelines in acute pancreatitis. 25 61
17032204 2006
42
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. 61 25
16699518 2006
43
Cigarette smoking accelerates progression of alcoholic chronic pancreatitis. 25 61
15753536 2005
44
Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. 25 61
11448279 2001
45
Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study. 25 61
10859041 2000
46
Hereditary pancreatitis. 25 61
7698830 1994
47
Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions. 25
31882447 2020
48
Primer on Precision Medicine for Complex Chronic Disorders. 25
31335357 2019
49
Parental influence on human germline de novo mutations in 1,548 trios from Iceland. 25
28959963 2017
50
Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. 25
28171547 2016
Sources

Variations for Pancreatitis

About this section

ClinVar genetic disease variations for Pancreatitis:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 TMEM67 NM_153704.6(TMEM67):c.1321C>T (p.Arg441Cys) SNV Likely pathogenic 217725 rs752362727 8:94798483-94798483 8:93786255-93786255
2 TMEM67 NM_153704.6(TMEM67):c.1843T>C (p.Cys615Arg) SNV Likely pathogenic 1383 rs201893408 8:94808198-94808198 8:93795970-93795970
3 CFTR NM_000492.4(CFTR):c.2991G>C (p.Leu997Phe) SNV Uncertain significance 7229 rs1800111 7:117250575-117250575 7:117610521-117610521
4 CFTR NM_000492.4(CFTR):c.1584G>A (p.Glu528=) SNV not provided 43576 rs1800095 7:117199709-117199709 7:117559655-117559655

Copy number variations for Pancreatitis from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 194974 5 147184338 147191453 Deletion SPINK1 Pancreatitis
2 220321 7 137300000 142800000 Triplication PRSS1 Pancreatitis
3 220322 7 137300000 142800000 Triplication PRSS2 Pancreatitis
4 221070 7 142136892 142140501 Triplication PRSS1 Pancreatitis
5 221298 7 142800000 147500000 Triplication PRSS1 Pancreatitis
Sources

Expression for Pancreatitis

About this section
Search GEO for disease gene expression data for Pancreatitis.
Sources

GO Terms for Pancreatitis

About this section

Cellular components related to Pancreatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 SST SPINK1 SCT REG3A REG1A PRSS2
2 extracellular space GO:0005615 9.5 SST SPINK1 SCT REG3A REG1A PRSS2
3 very-low-density lipoprotein particle GO:0034361 9.26 LPL APOC2
4 chylomicron GO:0042627 9.16 LPL APOC2

Biological processes related to Pancreatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.85 PRSS2 PRSS1 CTRC CPB1 CPA1
2 retinoid metabolic process GO:0001523 9.5 PNLIP LPL APOC2
3 cobalamin metabolic process GO:0009235 9.48 PRSS1 CTRC
4 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.43 PLA2G2A LPL
5 antimicrobial humoral response GO:0019730 9.43 REG3A PRSS2 PLA2G2A
6 very-low-density lipoprotein particle remodeling GO:0034372 9.4 LPL APOC2
7 chylomicron remodeling GO:0034371 9.37 LPL APOC2
8 lipid catabolic process GO:0016042 9.26 PNLIP PLA2G2A LPL APOC2
9 cell wall disruption in other organism GO:0044278 9.16 REG3A REG1A
10 digestion GO:0007586 8.92 SST PRSS2 PRSS1 CCK

Molecular functions related to Pancreatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.54 SST SCT CCK
2 peptidase activity GO:0008233 9.35 PRSS2 PRSS1 CTRC CPB1 CPA1
3 peptidoglycan binding GO:0042834 9.32 REG3A REG1A
4 lipase activity GO:0016298 9.26 PNLIP LPL
5 hydrolase activity GO:0016787 9.23 PRSS2 PRSS1 PNLIP PLA2G2A LPL CTRC
6 oligosaccharide binding GO:0070492 9.16 REG3A REG1A
Sources

Sources for Pancreatitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....